FDA-Approved Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices: An Updated Landscape

被引:80
作者
Joshi, Geeta [1 ,2 ]
Jain, Aditi [3 ]
Araveeti, Shalini Reddy [4 ]
Adhikari, Sabina [5 ]
Garg, Harshit [1 ]
Bhandari, Mukund [6 ]
机构
[1] UTHlth San Antonio, Dept Urol, San Antonio, TX 78229 USA
[2] UTHlth San Antonio, Dept Med Educ, San Antonio, TX 78229 USA
[3] UTHlth San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA
[4] New England Coll, Henniker, NH 03242 USA
[5] Texas A&M Univ, Dept Comp Sci, College Stn, TX 77843 USA
[6] UTHlth San Antonio, Greehey Children Canc Res Inst, San Antonio, TX 78229 USA
基金
英国科研创新办公室;
关键词
machine learning; artificial intelligence; FDA; medical devices; AI; ML; clinical trials; radiology;
D O I
10.3390/electronics13030498
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
As artificial intelligence (AI) has been highly advancing in the last decade, machine learning (ML)-enabled medical devices are increasingly used in healthcare. In this study, we collected publicly available information on AI/ML-enabled medical devices approved by the FDA in the United States, as of the latest update on 19 October 2023. We performed comprehensive analysis of a total of 691 FDA-approved artificial intelligence and machine learning (AI/ML)-enabled medical devices and offer an in-depth analysis of clearance pathways, approval timeline, regulation type, medical specialty, decision type, recall history, etc. We found a significant surge in approvals since 2018, with clear dominance of the radiology specialty in the application of machine learning tools, attributed to the abundant data from routine clinical data. The study also reveals a reliance on the 510(k)-clearance pathway, emphasizing its basis on substantial equivalence and often bypassing the need for new clinical trials. Also, it notes an underrepresentation of pediatric-focused devices and trials, suggesting an opportunity for expansion in this demographic. Moreover, the geographical limitation of clinical trials, primarily within the United States, points to a need for more globally inclusive trials to encompass diverse patient demographics. This analysis not only maps the current landscape of AI/ML-enabled medical devices but also pinpoints trends, potential gaps, and areas for future exploration, clinical trial practices, and regulatory approaches. In conclusion, our analysis sheds light on the current state of FDA-approved AI/ML-enabled medical devices and prevailing trends, contributing to a wider comprehension.
引用
收藏
页数:15
相关论文
共 29 条
[1]  
[Anonymous], 2023, PREMARKET APPROVAL P
[2]  
[Anonymous], Screening for Early Detection-CPR22
[3]  
[Anonymous], 2023, De Novo Classification Request FDA
[4]  
[Anonymous], 2022, CDCBreastCancer Breast Cancer Statistics
[5]  
[Anonymous], 2023, Premarket Notification 510(k)
[6]  
Artificial, 2023, Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices FDA
[7]  
Artificial Intelligence (AI) Coined at Dartmouth, 2018, Celebrate Our 250th
[8]   Guiding principles for the responsible development of artificial intelligence tools for healthcare [J].
Badal, Kimberly ;
Lee, Carmen M. ;
Esserman, Laura J. .
COMMUNICATIONS MEDICINE, 2023, 3 (01)
[9]   Diverse Research Teams and Underrepresented Groups in Clinical Studies [J].
Bains, Ashank ;
Osathanugrah, Pawarissara ;
Sanjiv, Nayan ;
Chiu, Cedrick ;
Fiorello, Marissa G. ;
Siegel, Nicole H. ;
Peeler, Crandall E. ;
Distefano, Alberto G. ;
Lee, Hyunjoo J. ;
Ness, Steven ;
Desai, Manishi A. ;
Titelbaum, Jenna R. ;
Pira, Tony ;
Lamattina, Kara C. ;
Christiansen, Stephen P. ;
Cabral, Howard J. ;
Subramanian, Manju L. .
JAMA OPHTHALMOLOGY, 2023, 141 (11) :1037-1044
[10]   Solving the explainable AI conundrum by bridging clinicians' needs and developers' goals [J].
Bienefeld, Nadine ;
Boss, Jens Michael ;
Luthy, Rahel ;
Brodbeck, Dominique ;
Azzati, Jan ;
Blaser, Mirco ;
Willms, Jan ;
Keller, Emanuela .
NPJ DIGITAL MEDICINE, 2023, 6 (01)